161 related articles for article (PubMed ID: 11738472)
21. Transglutaminases - possible drug targets in human diseases.
Gentile V; Cooper AJ
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
[TBL] [Abstract][Full Text] [Related]
22. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
[TBL] [Abstract][Full Text] [Related]
23. Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.
Lai TS; Tucker T; Burke JR; Strittmatter WJ; Greenberg CS
J Neurochem; 2004 Mar; 88(5):1253-60. PubMed ID: 15009681
[TBL] [Abstract][Full Text] [Related]
24. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic effects of cystamine in a murine model of Huntington's disease.
Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
[TBL] [Abstract][Full Text] [Related]
26. Transgenic mice in the study of polyglutamine repeat expansion diseases.
Bates GP; Mangiarini L; Davies SW
Brain Pathol; 1998 Oct; 8(4):699-714. PubMed ID: 9804379
[TBL] [Abstract][Full Text] [Related]
27. Polyglutamine pathogenesis.
Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
[TBL] [Abstract][Full Text] [Related]
28. Tissue transglutaminase is increased in Huntington's disease brain.
Lesort M; Chun W; Johnson GV; Ferrante RJ
J Neurochem; 1999 Nov; 73(5):2018-27. PubMed ID: 10537061
[TBL] [Abstract][Full Text] [Related]
29. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
30. Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length.
Cooper AJ; Sheu KR; Burke JR; Onodera O; Strittmatter WJ; Roses AD; Blass JP
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12604-9. PubMed ID: 9356496
[TBL] [Abstract][Full Text] [Related]
31. Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor.
Mandrusiak LM; Beitel LK; Wang X; Scanlon TC; Chevalier-Larsen E; Merry DE; Trifiro MA
Hum Mol Genet; 2003 Jul; 12(13):1497-506. PubMed ID: 12812978
[TBL] [Abstract][Full Text] [Related]
32. The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates.
de Cristofaro T; Affaitati A; Cariello L; Avvedimento EV; Varrone S
Biochem Biophys Res Commun; 1999 Jun; 260(1):150-8. PubMed ID: 10381359
[TBL] [Abstract][Full Text] [Related]
33. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
34. Transglutaminases as targets for pharmacological inhibition.
Wodzinska JM
Mini Rev Med Chem; 2005 Mar; 5(3):279-92. PubMed ID: 15777262
[TBL] [Abstract][Full Text] [Related]
35. The multifaceted role of transglutaminase in neurodegeneration: review article.
Karpuj M; Steinman L
Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
[TBL] [Abstract][Full Text] [Related]
36. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
Li SH; Li XJ
Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
[TBL] [Abstract][Full Text] [Related]
37. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
Burguera EF; Love BJ
Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
[TBL] [Abstract][Full Text] [Related]
38. Lysine residues of IGF-I are substrates for transglutaminases and modulate downstream IGF-I signalling.
Sivaramakrishnan M; Croll TI; Gupta R; Stupar D; Van Lonkhuyzen DR; Upton Z; Shooter GK
Biochim Biophys Acta; 2013 Dec; 1833(12):3176-3185. PubMed ID: 24036101
[TBL] [Abstract][Full Text] [Related]
39. Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. Integration with loricrin.
Candi E; Tarcsa E; Idler WW; Kartasova T; Marekov LN; Steinert PM
J Biol Chem; 1999 Mar; 274(11):7226-37. PubMed ID: 10066784
[TBL] [Abstract][Full Text] [Related]
40. Huntington's disease: molecular basis of neurodegeneration.
Rubinsztein DC; Carmichael J
Expert Rev Mol Med; 2003 Aug; 5(20):1-21. PubMed ID: 14585171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
